Overview of parametric survival analysis for health-economic applications

PharmacoEconomics

Volumn 31, Issue 8, 2013, Pages 663-675

  Ishak, K Jack ^a   Kreif, Noemi ^b   Benedict, Agnes ^c   Muszbek, Noemi ^c  

^a UNITED BIOSOURCE CORPORATION   (Canada)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

COMPUTER PROGRAM; HAZARD RATIO; HEALTH ECONOMICS; HUMAN; KAPLAN MEIER METHOD; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LOG RANK TEST; MULTICENTER STUDY (TOPIC); NORMAL DISTRIBUTION; OVERALL SURVIVAL; PARAMETRIC TEST; PATIENT CODING; PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; STATISTICAL PARAMETERS; SURVIVAL; SURVIVAL RATE; TIME;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MODELS, ECONOMIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 84881187599     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0064-3     Document Type: Review

References (29)

1. Cuzick J, Sestak I, Baum M, et al, ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135-1141.
2. Tappenden P, Chilcott J, Ward S, et al. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer. 2006;42:2867-75.
3. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics. 2005;23(4):323-32.
4. Latimer N. NICE DSU Technical Support Document 14: undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. 2011. http://www.nicedsu.org.uk.
5. Collett D. Modelling survival data in medical research. 2nd ed. London: Chapman & Hall/CRC; 2003.
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.
7. Kleinbaum DG, Klein M. Survival analysis: a self-learning text. Berlin: Springer; 2005.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn. 1958;53:457-81.
9. Siegel S. Non-parametric statistics for the behavioral sciences. New York: McGraw-Hill; 1956. p. 75-83.
10. Cox DR. Regression models and life-tables. J R Stat Soc Ser B Stat Methodol. 1972;34(2):187-220.
11. Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139.
12. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815-34.
13. StataCorp LP. STATA survival analysis and epidemiological tables. Reference manual, release 12. College Station: Stata Press; 2011.
14. Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. doi: 10.1186/1471-2288-12-9.
15. Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. Value Health. 2004;7(5):627-35.
16. Bebbington M, Lai CD, Zitikis R. Modeling human mortality using mixtures of bathtub shaped failure distributions. J Theor Biol. 2007;245(3):528-38.
17. Gray RJ. Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Statist Assn. 1992;87(420):942-951.
18. Royston P, Parmar MKB. Flexible parametric-hazards and proportional odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21:2175-97.
19. Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265-90.
20. Jackson CH, Sharples LD, Thompson SG. Survival models in health economic evaluations: balancing fit and parsimony to improve prediction. Int J Biostat. 2010;6(1):article 34.
21. Jackson CH, Thompson SG, Sharples LD. Accounting for uncertainty in health economic decision models by using model averaging. J R Stat Soc Ser A Stat Soc. 2009;172:383-404.
22. Muszbek N, Kreif N, Valderrama A, Benedict A, Ishak KJ, Ross P. Modeling survival in hepatocellular carcinoma. Curr Med Res Opin. 2012;28(7):1141-53.
23. Aballéa S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer. 2007;109(6):1082-9.
24. Castelli C, Combescure C, Foucher Y, et al. Cost-effectiveness analysis in colorectal cancer using a semi-Markov model. Stat Med. 2007;26(30):5557-71.
25. Shiroiwa T, Fukuda T, Shimozuma K, et al. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008;109(3):559-66.
26. Soini EJ, Martikainen JA, Nousiainen T. Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol. 2011;22(5):1189-97.
27. Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2008;12(15):ii-ix, xi-162.
28. Thompson Coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2010;14(2):1-184, iii-iv.
29. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(45):iii-iv, ix-221.